Ophthalmology CxO and Investor Roundtable in partnership with Carl Zeiss Meditech

As high interest rates and inflation continue to put pressure on the margins of ophthalmology groups, the playbook, particularly for private equity-backed groups has changed. Buy and build opportunities will only go so far and instead, groups must focus on other value-generating activities, process standardisation and optimisation to grow their top line.

The demographic tailwinds remain strong and the dawn of new therapeutics to treat Dry AMD means that there continue to be huge opportunities in the space. But challenges remain around full-reimbursement, new payment models and standardising care delivery.

Groups need to decide what services to offer mixed with the right commercial model. Do they have to offer a complete spectrum of services to be successful or can they pick and choose the activities with the best margin? How do they ensure that their models are sustainable and can deliver care for the medium to long term?

An image and data-rich discipline, the sector has the perfect conditions for AI and other technologies to make a huge and meaningful impact on patient access and outcomes. What investments should be made in tech and what has the potential to make the biggest impact?

This CxO roundtable discussion is an opportunity for providers and investors to come together in a non-competitive environment and discuss what the new ophthalmology playbook should be. It is a chance to bounce ideas off of one another and explore what investments in technology and infrastructure are needed to ensure the sector’s longevity and sustainability.

The roundtable features insights, lessons learned and follow-up discussion with contributions from:

Franz-Robert Klingen, Partner, Bain and Co
Darshak Shah, Founder and Non Executive Director, NewMedica
Johanna Oberg, CEO Commercial Care, Bergman Clinics
Gregory Shakarin, Head of AI, Carl Zeiss Meditech

This session is strictly limited by space and is by invitation only. You can apply for an invitation via this form.

Speakers

HBI 2024 Annual Leadership Dinner

By invitation only.

Speakers

What is the winning model in occupational health?

European markets are experiencing significant labour shortages, a trend sharpened by all-time-high employee sickness rates. Employers are now increasingly relying on Occupational Health providers that promise lower employee absence days, better talent recruitment and higher workforce productivity. The growth drivers in these businesses combined low-regulation, predominantly B2B and stable revenue models makes it an attractive space for investors. This session explores how such services are impacting employee health and what the best model to win in the space is. How does integration with primary care, PMI and tech-enablement transform delivery and scale access?

Moderator and investment overview: Reiner Hepberger, Managing Director, Houlihan Lokey

Speakers:
Petri Bono, Chief Medical Officer, Terveystalo
Jack Latus, CEO, Latus Group
Alex Goldsmith, CEO, Medigold Health

Speakers

Rainer HepbergerManaging DirectorHoulihan Lokey

Petri BonoChief Medical OfficerTerveystalo

Jack LatusChief Executive OfficerLatus Group

Alex GoldsmithCEOMedigold Health